Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, Status and Forecast 2024-2031

Report ID: 922531 | Published Date: Jan 2025 | No. of Page: 97 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Eteplirsen
        1.2.3 Deflazacort
        1.2.4 Ataluren
    1.3 Market by Application
        1.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Home Care
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Perspective (2016-2027)
    2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Growth Trends by Regions
        2.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Share by Regions (2016-2021)
        2.2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Regions (2022-2027)
    2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Dynamic
        2.3.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Trends
        2.3.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
        2.3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
        2.3.4 Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue
        3.1.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue (2016-2021)
        3.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2016-2021)
    3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue
    3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio
        3.4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2020
    3.5 Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Head office and Area Served
    3.6 Key Players Drugs for Duchenne Muscular Dystrophy (DMD) Product Solution and Service
    3.7 Date of Enter into Drugs for Duchenne Muscular Dystrophy (DMD) Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Type
    4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Type (2016-2021)
    4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2022-2027)

5 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Application
    5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Application (2016-2021)
    5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
    6.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
        6.2.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
        6.2.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
        6.2.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
    6.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
        6.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
        6.3.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
        6.3.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
    6.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
        6.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
        6.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
    7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
        7.2.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
        7.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
        7.2.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
    7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
        7.3.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
        7.3.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
        7.3.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
    7.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
        7.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
        7.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
    8.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
        8.2.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
    8.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
        8.3.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
    8.4 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region
        8.4.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
    9.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
        9.2.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
        9.2.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
        9.2.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
    9.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
        9.3.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
        9.3.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
        9.3.3 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
    9.4 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
        9.4.1 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
        9.4.2 Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2016-2027)
    10.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
        10.2.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2027)
    10.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
        10.3.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2027)
    10.4 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
        10.4.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Sarepta Therapeutics
        11.1.1 Sarepta Therapeutics Company Details
        11.1.2 Sarepta Therapeutics Business Overview
        11.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.1.4 Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.1.5 Sarepta Therapeutics Recent Development
    11.2 PTC Therapeutics
        11.2.1 PTC Therapeutics Company Details
        11.2.2 PTC Therapeutics Business Overview
        11.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.2.4 PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.2.5 PTC Therapeutics Recent Development
    11.3 Pfizer
        11.3.1 Pfizer Company Details
        11.3.2 Pfizer Business Overview
        11.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.3.4 Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.3.5 Pfizer Recent Development
    11.4 Bristol-Myers Squibb
        11.4.1 Bristol-Myers Squibb Company Details
        11.4.2 Bristol-Myers Squibb Business Overview
        11.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.4.4 Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.4.5 Bristol-Myers Squibb Recent Development
    11.5 Italfarmaco
        11.5.1 Italfarmaco Company Details
        11.5.2 Italfarmaco Business Overview
        11.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.5.4 Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.5.5 Italfarmaco Recent Development
    11.6 Santhera Pharmaceuticals
        11.6.1 Santhera Pharmaceuticals Company Details
        11.6.2 Santhera Pharmaceuticals Business Overview
        11.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.6.4 Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.6.5 Santhera Pharmaceuticals Recent Development
    11.7 WaVe life Science
        11.7.1 WaVe life Science Company Details
        11.7.2 WaVe life Science Business Overview
        11.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Introduction
        11.7.4 WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
        11.7.5 WaVe life Science Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Eteplirsen
    Table 3. Key Players of Deflazacort
    Table 4. Key Players of Ataluren
    Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions (2016-2021)
    Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions (2022-2027)
    Table 11. Drugs for Duchenne Muscular Dystrophy (DMD) Market Trends
    Table 12. Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
    Table 13. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
    Table 14. Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
    Table 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players (2016-2021)
    Table 17. Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2020)
    Table 18. Ranking of Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Drugs for Duchenne Muscular Dystrophy (DMD) Product Solution and Service
    Table 22. Date of Enter into Drugs for Duchenne Muscular Dystrophy (DMD) Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2016-2021)
    Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2016-2021)
    Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Sarepta Therapeutics Company Details
    Table 63. Sarepta Therapeutics Business Overview
    Table 64. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 65. Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 66. Sarepta Therapeutics Recent Development
    Table 67. PTC Therapeutics Company Details
    Table 68. PTC Therapeutics Business Overview
    Table 69. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 70. PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 71. PTC Therapeutics Recent Development
    Table 72. Pfizer Company Details
    Table 73. Pfizer Business Overview
    Table 74. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 75. Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 76. Pfizer Recent Development
    Table 77. Bristol-Myers Squibb Company Details
    Table 78. Bristol-Myers Squibb Business Overview
    Table 79. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 80. Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 81. Bristol-Myers Squibb Recent Development
    Table 82. Italfarmaco Company Details
    Table 83. Italfarmaco Business Overview
    Table 84. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 85. Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 86. Italfarmaco Recent Development
    Table 87. Santhera Pharmaceuticals Company Details
    Table 88. Santhera Pharmaceuticals Business Overview
    Table 89. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 90. Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 91. Santhera Pharmaceuticals Recent Development
    Table 92. WaVe life Science Company Details
    Table 93. WaVe life Science Business Overview
    Table 94. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product
    Table 95. WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021) & (US$ Million)
    Table 96. WaVe life Science Recent Development
    Table 97. Research Programs/Design for This Report
    Table 98. Key Data Information from Secondary Sources
    Table 99. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type: 2020 VS 2027
    Figure 2. Eteplirsen Features
    Figure 3. Deflazacort Features
    Figure 4. Ataluren Features
    Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application: 2020 VS 2027
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Home Care Case Studies
    Figure 9. Drugs for Duchenne Muscular Dystrophy (DMD) Report Years Considered
    Figure 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions: 2020 VS 2027
    Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Regions (2022-2027)
    Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players in 2020
    Figure 15. Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2020
    Figure 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2016-2021)
    Figure 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2022-2027)
    Figure 19. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
    Figure 21. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
    Figure 22. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
    Figure 23. United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
    Figure 27. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
    Figure 28. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
    Figure 29. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2016-2027)
    Figure 39. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
    Figure 47. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
    Figure 48. Latin America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
    Figure 49. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2016-2027)
    Figure 55. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Sarepta Therapeutics Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 59. PTC Therapeutics Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 60. Pfizer Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 62. Italfarmaco Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 64. WaVe life Science Revenue Growth Rate in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2016-2021)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science
Frequently Asked Questions
Drugs for Duchenne Muscular Dystrophy (DMD) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Drugs for Duchenne Muscular Dystrophy (DMD) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Drugs for Duchenne Muscular Dystrophy (DMD) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports